News Hub | News Direct

Kevel Named to Newsweek’s List of The Top 200 America’s Most Loved Workplaces for 2024

Kevel

Newsweek Magazine today published the annual America’s Top Most Loved Workplaces® list, developed by Most Loved Workplace®, a division of Best Practice Institute (BPI). Kevel has been honored with a place in the top 20, being ranked # 18 out of the 200 companies included in the list. This marks the fourth annual Most Loved Workplace® list. This year, the list has expanded to the Top 200, reflecting companies' growing commitment to prioritizing employee sentiment and creating workplaces that employees love. The results were determined after surveying more than 2.6 million employees from businesses with workforces varying in size from less than 50 to more than 10,000. The list recognizes companies that put respect, caring, and appreciation for their employees at the center of their business model and, in doing so, have earned the loyalty and respect of the people who work for them. “We are so proud about our inclusion on the Most Loved Workplace® list,” said Mike Kohn, Chief People Officer at Kevel. “We have focused on building a people-first organization since our founding, and have used our values as a north star as we scaled our company. We routinely use engagement surveys and qualitative check-ins both to keep a pulse on how we are working as well as to identify trends and insights that enable us to drive actions in support of building a workplace where everyone can thrive.” How positive workers feel about their future at the company, career achievement, how much employer values align with employee values, respect at all levels, and the level of collaboration at the firm were the five critical areas measured to gauge employee sentiment. In addition, areas such as inclusion, diversity, equity and belonging, career development, and company leadership were identified and analyzed in relation to the five critical areas measured. “It’s inspiring to see the list expand this year to 200 companies, a clear indication that organizations are truly committed to creating workplaces where employees feel valued and connected. We’re thrilled to celebrate their achievements as this recognition continues to grow.” - Nancy Cooper, Newsweek’s Global Editor in Chief To view Kevel’s ranking and the top honored companies view the Top 20 Most Loved Workplaces in America or view the full list of the 2024 America’s Top 200 Most Loved Workplaces®. About Kevel Kevel powers world-class retail media networks with the Retail Media Cloud™. With the combination of the Kevel Ad Server and Kevel Audience, multi-brand retailers, marketplaces, and ecommerce companies can launch limitless ad formats and unique targeting segments online and in-store, all with closed-loop attribution. Kevel believes that every digital retailer should have the capability to scale their own distinct ad platform, just like big tech players like Amazon. Customers like Edmunds, Klarna, Delivery Hero, Leroy Merlin, Slickdeals, and other leading retailers and marketplaces all launched their own retail media network with Kevel. The company has garnered numerous accolades, most recently earning recognition as one of the leading 100 innovative tech start-ups driving the future of brand-to-consumer in 2023 and awarded the MarTech Breakthrough Award for best overall ad tech company in 2022. Learn more at www.kevel.com. About Newsweek Newsweek is the modern global digital news organization built around the iconic, over 90-year-old American magazine. Newsweek reaches 100 million people each month with its thought-provoking news, opinion, images, graphics, and video delivered across a dozen print and digital platforms. Headquartered in New York City, Newsweek also publishes international editions in EMEA and Asia. About Best Practice Institute Best Practice Institute is an award-winning leadership and organization development center, benchmark research company, think tank, and solutions provider. BPI is the only certifying body for Most Loved Workplace® and conducted the original research to create the model and criteria for becoming a Most Loved Workplace®. BPI’s research proves that Most Loved Workplaces® produce 3-4 times better customer service, employee performance, and retention than companies not loved by their employees. For more information on how to apply to become a certified Most Loved Workplace, go to: http://www.mostlovedworkplace.com Contact Details Kevel Jennifer Choo Director of Marketing +1 973-343-8819 jchoo@kevel.com

October 02, 2024 10:00 AM Eastern Daylight Time

Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204

Global Markets News

Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today. The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients. Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies. While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer. Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers. Click here to read Silexion's full announcement *** This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

October 01, 2024 11:47 AM Eastern Daylight Time

COLORESCIENCE® INTRODUCES TOTAL LASH™ MASCARA

Colorescience

Colorescience®, a leading dermatologist-recommended specialty skincare company, is launching Total Lash™ Mascara, an innovative, new all-in-one lash serum, conditioner and mascara that immediately enhances the appearance of lash length and volume for a vibrant, eye-opening effect. With every application, this clinically tested formula works to improve lash health with a blend of peptides and botanicals that nourishes the lashes while helping support the natural lash cycle for healthier, stronger, fuller and longer looking lashes. The Total Lash™ ingredient complex uses gentle, prostaglandin analogue-free ingredients and has been ophthalmology tested and confirmed to be safe for sensitive eyes and contact lens wearers. This formula is ideal for those who want to restore and improve their natural lashes, especially after discontinuing lash extensions, false lashes, or other lash procedures. Dr.Tanya Khan, Oculoplastic Surgeon and Board-Certified Ophthalmologist, led the clinical study. After a 12-week clinical trial with daily usage of Total Lash Mascara 90% of subjects reported their lashes looked longer. As measured by Dr. Khan, lashes were on average 24% longer compared to baseline. Over 92% of subjects reported less lash breakage and 94% reported lashes appeared fuller, thicker, and fluffier after twelve weeks of usage. Recalling these results, Dr. Khan shared, “During the clinical study, it became clear to me that patients were readily achieving their desired results of lash growth, density, thickness, and darkness when using the Total Lash™ product once per day. As an oculoplastic surgeon and ophthalmologist, I am even more amazed that the formula is well-tolerated by sensitive eyes and does not cause irritation or discoloration of the delicate skin around the eye area. I look forward to offering this product to my patients as a safe, effective, and gentle daily option that delivers lash enhancement without prostaglandins or extensions.” This multi-benefit formula enhances the appearance of length and volume, nourishes and strengthens the lashes and supports lash growth. Proven peptide Myristoyl Pentapeptide-17 stimulates the hair follicle to help support continued growth while botanical extracts optimize root health and help promote continued growth for longer, fuller looking lashes. The results are a visibly denser, more defined lash line and longer lashes that are hydrated and nourished. Panthenol and jojoba seed oil condition and nourish lashes to reduce breakage helping strengthen and prolong length and volume. Lastly, the formula immediately enhances lashes upon application while providing all-day smudge-free wear. This tubing mascara wraps each lash in a rich black iron oxide mineral pigment, making this dye-free formula ideal for sensitive eyes. Patricia Boland, VP of Research & Development at Colorescience says, “We created this formula with the tubing feature because our goal is always to treat and improve while delivering immediate enhancement and optimal wear. The skin around the eyes is especially thin and delicate, so extensive rubbing during removal of products can contribute to irritation. Instead, our Total Lash Mascara envelops each lash with our clinically proven treatment complex while maximizing wear-time, and the product removes effortlessly with warm water and a favorite cleanser.” ABOUT COLORESCIENCE Colorescience ®, the leading innovator in all-mineral sun protection, delivers transformational skincare solutions through wearable multifunctional products that provide immediate confidence and long-term visible results. Crafted for users who know that great results require daily skincare and protection, Colorescience ® uses cutting-edge technology and clinically tested formulas to ensure efficacy and provide reassurance to people of all ages, skin types, and concerns. Colorescience ® products speak for themselves through their wearability, published clinical studies, and skin-healthy ingredients. For more information please contact: Project MM, meredith@projectmmnyc.com Contact Details Meredith Winfrey meredith@projectmmnyc.com Company Website https://www.colorescience.com

October 01, 2024 08:00 AM Eastern Daylight Time

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

Leading Beauty Retailer Credo Beauty Debuts Private Label Skincare Line: Credo Skincare

Credo Beauty

Credo, the specialty clean beauty retail pioneer, is proud to announce the launch of its own eponymous skincare line, Credo Skincare. The specialty retailer has raised the bar introducing a benefit-driven collection of skincare products focused on the #1 skin concern gathered from clients – hydration – while continuing to challenge and elevate standards for clean and sustainable products and packaging. A cohesive easy to navigate cleanser and moisturizer system meets wanted gold standards. A decade ago, Credo disrupted an underregulated industry as a catalyst for positive change spurring a tidal wave of conscientious product and packaging innovation. Now after accruing 10 years of customer feedback, experience, and data Credo Skincare was developed according to what they found matters most. Ultimately hydration was the stand-out concern for clients. And through in-depth analysis, Credo determined the top ingredient and search terms according to what customers want from their products to deliver that and more. Through their access to the best in business partners, they created results-driven formulas packed with clinically proven actives and sustainably- minded packaging - every aspect of Credo Skincare is transparent and powerfully effective. Credo Skincare’s first collection is comprised of two cleansers ($44 each) and four moisturizers ($64 each) that service skin conditions surrounding primary concerns - dry skin, sensitivity and redness, dullness, and aging - by nourishing the skin and protecting its microbiome through today’s most powerful active combinations. Their formulations are based on key ingredient search terms and skincare concerns. As well, each product contains the transformative power of upcycled vetiver root extract, ethically harvested by a local cooperative in Haiti. Vetiver root is an antioxidant-loaded, potent wonder grass that supports the protection of the skin’s barrier for a vibrant skin tone and a nourished complexion while improving skin texture and reducing the appearance of pores and wrinkles. Credo Skincare’s goals are to provide an easy two step, effective regimen for healthy, hydrated skin that makes customers look and feel their best. Clinicals have proven 27% improvement in hydration after 24 hours, 31% improvement in hydration instantly, and an improvement in the skin barrier function instantly and after 24 hours. ● Deep Thirst Hydrating Cleanser ($44): A transformative formula to deeply cleanse while retaining moisture. ● True Timeout Calming Cleanser ($44): Designed to soothe and calm sensitive skin. ● Deep Thirst Hydrating Moisturizer ($64): Provides intense hydration with lasting effects. ● True Timeout Calming Moisturizer ($64): Helps alleviate sensitivity and redness. ● Radiance Rising Brightening Moisturizer ($64): Brightens dull skin and enhances radiance. ● Rewinder Anti-Aging Moisturizer ($64): Reduces the appearance of wrinkles and fine lines. Beyond that as a retailer, Credo Beauty continues to drive the packaging and social standards that are the hallmarks of tomorrow. Every pump and cap in the Credo Skincare collection is comprised of a first-of-its kind PCR resin, including beauty waste packaging collected in Credo Beauty stores nationwide through Pact Collective, the non-profit Credo Beauty co-founded to divert beauty packaging from landfills. ● The Credo pump was created with Pact’s NewMatter material, a mixture of hard-to-recycle material or landfill and ocean-bound plastic. ● The first run of NewMatter pumps eliminated the need for 500 kg of virgin plastic (500 kg of recycled plastic used is equivalent to 11 cubic meters of landfill space or ~2,900 gallons of space!) ● Every 38 pumps eliminate one pound of material going to the landfill or ocean. “The benefit of listening to 10 years of customers' desires and skin concerns compelled us to create this line. Years of data drove the ingredient compositions of these products so that we could exceed our customers’ expectations for efficacy. Our Credo Clean Standard is already rigorous and difficult to attain but we wanted to challenge ourselves with how our own brand could take clean innovation to new heights from full disclosure of fragrance ingredients and packaging innovation to exceeding the minimum requirements to check certain boxes, Credo Skincare raises the bar on what is possible and what can become the future baseline,” says Co-Founder and CEO Annie Jackson. Availability: Credo Skincare will be available for purchase starting September 12, 2024, at all Credo brick and mortar store locations and on www.credobeauty.com. Media Contact: press@credobeauty.com About Credo Beauty: Credo Beauty offers today’s largest clean and sustainably minded beauty assortment in North America, across color, skincare, haircare and fragrance, partnering with over 120 leading brands, such as Westman Atelier, ILIA, OSEA, True Botanicals and LolaVie. Having built the strictest and lengthy guidelines, “The Credo Clean Standard™”, customers can trust that they are purchasing the most effective, innovative products with safer ingredients with an emphasis on sustainable, natural and ethical materials. Trained makeup artists and estheticians (who are continually being educated by Credo Beauty and our brands) offer an exceptional experience both in-store and online. Visit one of the 15 brick-and-mortar store locations or www.credobeauty.com. Credo Beauty is backed by Next World Evergreen, a San Francisco-based private equity firm that invests in conscious consumer brands across sectors like clean beauty, personal care, health and wellness, sustainable lifestyle, and better-for-you food and beverage. Visit https://www.nextworldevergreen.com/ About Pact Collective: With an industry that generates over 120 billion packages every year, most ending up in landfill – they’re often too small, too flexible, or made of too many materials to be traditionally recycled. All those tiny cosmetic contraptions? They’re headed for the trash. Pact is a nonprofit collective uniting the beauty industry to take responsibility for our packaging waste and work collaboratively toward circular packaging solutions. Visit https://www.pactcollective.org/ Contact Details Amanda Smeal +1 844-692-7336 press@credobeauty.com

September 12, 2024 08:04 AM Eastern Daylight Time

Image

NAVEX Announces 2024 Excellence Awards Finalists

NAVEX Global

NAVEX, a leading provider of integrated risk and compliance management software, announces today the 2024 NAVEX Excellence Awards finalists. Now in its fourth year, the awards celebrate organizations that demonstrate exceptional commitment to corporate governance, risk mitigation, and ethical practices. Each year, the NAVEX Excellence Awards highlight how robust governance, risk and compliance (GRC) programs can strengthen corporate culture and meaningfully impact business outcomes that matter. The 2024 finalists exemplify how effective GRC initiatives can proactively manage and mitigate risks when woven into the organizational fabric. "Congratulations to this year’s nominees and finalists for their outstanding achievements," said NAVEX Chief Customer Officer, Steve Chapman. "We are proud to partner with customers who are dedicated to advancing their GRC efforts. These awards shine a spotlight on some of the most innovative and effective programs in the industry, and we applaud the compliance teams at these companies for their ongoing efforts to build highly ethical, risk-aware organizations." The winners will be honored in several categories, including Ethics & Compliance, Risk Management, and Risk and Compliance Program of the Year. Selected from a highly competitive pool of nominations, this year’s finalists include: As in previous years, the judging panel brings together a mix of NAVEX leaders and seasoned GRC professionals. This year’s esteemed panel features: Barbara Boehler, Senior Director, Program on Corporate Compliance and Ethics, Fordham Law Bill Cameron, Founder and Principal, Cameron Advisory Services Carol Williams, CEO and Enterprise Risk Management Consultant, Strategic Decision Solutions Carrie Penman, Chief Risk and Compliance Officer, NAVEX Kyle Brasseur, Former Editor in Chief, Compliance Week Kyle Martin, Vice President of GRC Solutions, NAVEX Matt Kelly, Editor and CEO, Radical Compliance LLC Stephen Chapman, Chief Customer Officer, NAVEX Vera Cherepanova, Ethics Advocate, Consultant, Author, Studio Etica Award recipients will be announced after to the 2024 NAVEX Next Virtual Conference on October 1. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

September 03, 2024 08:06 AM Eastern Daylight Time

Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data

Global Markets News

Nuvectis Pharma (NASDAQ: NVCT) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation for its lead candidate, NXP800. This designation, specifically for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers, marks a critical step forward in Nuvectis’s mission to address unmet needs in oncology. Orphan Drug Designation: A Strategic Advantage The FDA’s Orphan Drug Designation is awarded to drugs that show promise in treating rare diseases affecting fewer than 200,000 people in the U.S. For Nuvectis, this designation not only validates the potential of NXP800 but also provides several strategic benefits. These include tax credits for clinical trial costs, exemption from certain FDA fees, and potentially seven years of market exclusivity upon approval. NXP800 targets ARID1a-deficient cancers, a subset of ovarian cancers that present significant treatment challenges. The Orphan Drug Designation underscores the importance of this candidate in potentially offering a new, more effective treatment option for patients with this specific genetic mutation. Background and Market Impact This latest achievement builds on Nuvectis Pharma’s earlier successes. Earlier this year, the FDA granted Fast Track Designation to NXP800 for its development in platinum-resistant, ARID1a-mutated ovarian cancer. The Fast Track status, combined with the Orphan Drug Designation, highlights the urgent need for innovative treatments in this space and positions NXP800 as a potential game-changer in oncology. Financial analysts have taken note of Nuvectis’s progress. H.C. Wainwright recently reiterated its buy rating for Nuvectis, setting a price target of $21. This optimistic outlook reflects the market’s confidence in the company’s strategic direction, particularly as it prepares to release key clinical data later this year. Anticipation for Upcoming Results The next few months are expected to be pivotal for Nuvectis Pharma. The company is poised to share updates from its ongoing Phase 1b clinical trial of NXP800, which targets patients with platinum-resistant, ARID1a-mutated ovarian cancer. This trial is being closely watched, as positive results could significantly advance the development of NXP800, bringing it closer to pivotal trials and eventual regulatory approval. Additionally, Nuvectis is also conducting a Phase 1a dose escalation study for NXP900, its second key candidate, which targets YES1/SRC-driven tumors. Updates from this study are expected to provide further insights into the safety and potential efficacy of NXP900. ### Nuvvectis' Full announcment, titled " Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers" was published on August 29th, 2024. ### This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. https://justpaste.it/fcm9n/pdf. Global Markets News Network is a commercial digital brand compensated to provide coverage of innovative companies and industries and it is thus subject to conflicts of interest. Contact Details Global Markets News News Coverage ronald@futuremarketsresearch.com

August 29, 2024 08:20 AM Eastern Daylight Time

Navigate your Investment Roadmap with Select Sector SPDR ETFs

Select Sector SPDR

In an era where market dynamics shift as swiftly as the winds, Select Sector SPDR ETFs remain a beacon for investors aiming to harness the potential of sector-specific investments. Tailored to meet the diverse needs of both individual and institutional investors, these ETFs chart a course for strategic portfolio management by distilling the vast S&P 500 into accessible segments. Focused Investment Across Diverse Sectors Select Sector SPDR ETFs stand out by offering a focused approach to investing, breaking down the broad landscape of the S&P 500 into key sectors. This segmentation allows investors to pinpoint their investments according to specific economic areas, aligning their portfolios with their investment goals, risk assessments, and market perspectives. Below is a glimpse into the diverse holdings that form the core of the Select Sector SPDR ETFs: Communication Services Select Sector SPDR Fund (XLC): Zooms in on the telecommunications and media sectors, capturing the pulse of digital communication. Consumer Discretionary Select Sector SPDR Fund (XLY): Targets the vibrant consumer goods and services sector, from retail giants to entertainment behemoths. Consumer Staples Select Sector SPDR Fund (XLP): Focuses on essential consumer goods and services, providing stability in fluctuating markets. Energy Select Sector SPDR Fund (XLE): Powers through with a dedicated look at the energy sector, from fossil fuels to renewable resources. Financials Select Sector SPDR Fund (XLF): Encompasses the robust banking, investment, and insurance industries, the backbone of economic infrastructure. Health Care Select Sector SPDR Fund (XLV): Centers on the pharmaceuticals, healthcare equipment, and services sectors, addressing global health needs. Industrials Select Sector SPDR Fund (XLI): Broadens the horizon with manufacturing, construction, and logistics firms. Materials Select Sector SPDR Fund (XLB): Covers the foundational chemicals, construction materials, and packaging industries. Real Estate Select Sector SPDR Fund (XLRE): Opens doors to commercial real estate services and REITs. Technology Select Sector SPDR Fund (XLK): Accelerates into the information technology and electronics sectors, powering innovation and connectivity. Utilities Select Sector SPDR Fund (XLU): Illuminates the path with utility companies, ensuring the flow of essential services. A Path for Strategic Investment By offering a lens through which to invest in specific sectors, Select Sector SPDR ETFs enable investors to steer their portfolios with confidence and clarity. The ETFs’ commitment to transparency and strategic focus empowers investors to adapt and thrive amidst the ebb and flow of market conditions. In the evolving landscape of the financial markets, Select Sector SPDR ETFs stand as a testament to the power of targeted investment. Through detailed sector analysis and dedicated portfolio exposure, these ETFs offer a distinguished pathway for those seeking to refine their investment strategies with sector-specific allocations. About Select Sector SPDR ETFs Select Sector SPDR ETFs are a series of exchange-traded funds designed to provide investors with an effective way to engage in sector-specific investment strategies. By segmenting the S&P 500 into distinct sectors, Select Sector SPDR ETFs furnish investors with the tools necessary for targeted and strategic investment decisions. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007734 EXP 10/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

August 22, 2024 05:00 AM Eastern Daylight Time

Avenue Z Announces Strategic Partnerships with TikTok Shops and Shopify: Driving New Advancements in Social Commerce

Avenue Z

Heading into the crucial Q4 holiday retail season, Avenue Z, a media and technology company, announced its strategic partnerships with TikTok Shops and Shopify. These collaborations amplify Avenue Z’s cutting-edge approach, highlighting its role as an official TikTok Shops Agency Partner and Shopify Plus Partner, delivering unmatched benefits to shoppers, creators, and brands. Avenue Z, a leader in social commerce, is renowned for its ability to drive influence across all channels, where Shopify’s e-commerce platform and TikTok Shops’ affiliate and influencer marketing abilities are a critical part. “Shopify and TikTok Shops are the key drivers paving the new path that is social commerce” said David Corchado, Chief Strategy Officer at Avenue Z, and Head of Channel Partnerships. “They continue to innovate store functionality and enhance the on-platform shopper experience. Now with the prioritization of TikTok Live content, any DTC / B2C brand heading into the holiday retail season must have these two pieces in their e-commerce ecosystem, or they’ll miss the mark on Q4 performance.” This partnership provides direct access to TikTok Shop expertise, along with insights from Shopify and Shopify Plus experts, all designed to optimize the shopping experience, boost revenue, and enhance brand reputation. Avenue Z will also be working with brands on TikTok to stream “LIVE” content allowing viewers and creators to interact in real-time. Easy Access to TikTok Shop Expertise for Brands With over 150 million monthly active users in the US, TikTok is revolutionizing social commerce. Avenue Z’s status as a preferred TikTok Shops Partner (TSP) allows brands to tap into platform expertise and support to leverage viral marketing trends, transforming product discovery into instant purchasing decisions. This collaboration enables brands to easily engage with TikTok’s dynamic audience through Avenue Z’s expertise and creator network, leveraging real-time analytics and advanced tools to maximize sales and brand presence. “Affiliate and influencer marketing have evolved and merged into a highly effective strategy for performance marketing,” said Jonathan Snow, Chief Innovation Officer at Avenue Z, in a recent Fast Company article. “Brands can make the most of this by engaging a large number of affiliates and offering attractive commissions, all through the TikTok Shop platform. Paired with our platform expertise, social commerce will be a critically important revenue generating channel for brands in Q4.” Shopify Expertise for eCommerce Brands As a Shopify Plus Partner, Avenue Z helps brands optimize their digital storefronts and expand their reach, driving growth in a competitive marketplace. With Shopify, brands can manage and grow their online presence across multiple channels, ensuring a seamless shopping experience that meets the evolving preferences of today’s consumers. “This is why our Shopify Plus Partner status is so important, we’re able to bring the best in e-commerce to our clients,” said Snow. “Shopify has the world’s highest converting checkout experience, augmented by Shop Pay which expedites the payment process and offers consumers rewards and cashback. Thanks to this, Shopify Payments represents a staggering 61% of Shopify’s GMV, which climbed $2B in Q2 2024 (YoY), and was able to do so despite unfavorable consumer market conditions. When the tide turns and we enter a stronger consumer market in the near future, just imagine what Shopify’s growth will accelerate to.” Snow’s outlook for DTC/B2C brand performance in Q4 2024 remains strong, but only when best-in-class e-commerce tools and talent align, as is the case with Avenue Z’s Shopify Plus Partnership. Biggest Brand Benefits: Driving Revenue, Elevating Reputation As Avenue Z continues to pioneer advancements in social commerce, the strategic partnerships with TikTok Shops and Shopify mark a significant milestone. “Channels like this - TikTok and Shopify - are critical avenues for driving influence today, for brands looking to elevate reputation or increase revenue,” said Jeffrey Herzog, Founder, Chairman, and CEO of Avenue Z. “They are top performers in our channel network, excelling at driving commerce, connections, and conversions for our clients. We will undoubtedly expand in this area by adding more channels and expertise in the coming months." These partnerships highlight Avenue Z's continuous effort to stay at the forefront of innovation, ensuring that their clients can leverage the latest technological advancements to captivate and engage audiences across all channels. About TikTok Shop & TikTok Shop Partners (TSPs): TikTok Shops is a completely personalized and fully integrated commerce solution, where sellers can authentically connect with creators and communities to drive meaningful shopping experiences. Their network of experienced TikTok Shop Partners (TSPs) offer a range of services to sellers, enabling them to scale business on TikTok Shop effectively. About Shopify & Shopify Plus Partners: Shopify is the #1 complete commerce platform that lets anyone start, manage, and grow an e-commerce business. By bundling commerce activities into a single platform, business owners can sell in multiple places, across multiple channels, and integrate features and functionality that shape the future of commerce. Shopify Partners make up a diverse ecosystem across all segments of ecommerce, helping brands to innovate and implement faster. About Avenue Z: Avenue Z is a media and technology company breaking traditional boundaries between digital marketing, advertising and strategic communications. Our unique combination of smart media and smart content, informed by data science, has proven to increase a brand’s revenue and elevate its reputation. From the Wall Street Journal to TikTok, PR to social and search, our approach yields outcomes in commerce, connections, and conversion across all channels. With experts based in Miami, New York, and Orlando, serving a global roster of category leading brands - we drive influence. Visit www.avenuez.com Contact Details Avenue Z +1 407-637-2833 press@avenuez.com Company Website https://www.avenuez.com

August 20, 2024 08:15 AM Eastern Daylight Time